Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer

Table 2 Treatment delivery and subsequent therapies

	Median	Range	n	%
MMC/capecitabine	2.0	0.5-9.0
Cycles administrated
Duration of treatment (mo)	2.8	0.5-20.0
Patients beginning Tx at full dosage
MMC
Capecitabine			114	95.8
			45	37.8
Dose reductions
MMC			3	2.5
Capecitabine			16	13.5
Any			19	16.0
Dose intensity (median)
MMC (mg/m²/wk)	1.17	0.6-1.6
Capecitabine (g/m²/wk)	9.33	4.6-11.9
Treatment delay (> 3 d)
Yes			22	18.5
No			97	81.5
Reason for discontinuation
Progression			108	90.8
Toxicity			6	5.0
Other/unknown			5	4.2
Subsequent therapies
Any			35	29.4
Oxaliplatin			12	10.1
Irinotecan			8	6.7
5-FU			18	15.1
Bevacizumab			3	2.5
Cetuximab/panitumumab			6	5.0
Regorafenib			5	4.2
TAS-102			5	4.2
Other/clinical trial			8	6.7
None			84	70.6

MMC: Mitomycin C; Tx: Treatment; 5-FU: 5-fluorouracil.